Oragenics raises ~$840K in private placement; issues Series E Preferred with super voting rights

ORAGENICS INC

Gross proceeds of approximately $840,000 from issuance of 404,728 shares of common and 404,728 shares of Series E Preferred.
Series E Preferred carries 2,500 votes per share solely to approve a proposed amendment increasing authorized common from 4,166,666 to 350,000,000.
Series E Preferred automatically cancelled upon effectiveness of the amendment; no dividends and no trading market.
Net proceeds to be used for general corporate purposes; offering closed August 4, 2023.
Investors have agreed to vote Series E in the same proportion as common shares on the amendment.

item 1.01 item 5.03 item 3.02 item 3.03 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

ORAGENICS INC: Filed Certificate of Designation creating Series E Preferred Stock with specific voting and liquidation terms, contingent on an Amendment.

Change: charter amendment

Exact text from the filing

In connection with the Offering, the Company filed a Certificate of Designation with the Secretary of State for the State of Florida (the “Certificate of Designation”) designating 404,728 shares out of the authorized but unissued shares of its preferred stock as Series E Preferred Stock.

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

ORAGENICS INC entered into Securities Purchase Agreement with two healthcare-focused investors (effective 2023-08-04).

Action: entry
Agreement: equity purchase
Counterparty: two healthcare-focused investors
Effective: 2023-08-04

Exact text from the filing

On August 4, 2023, Oragenics, Inc. (the "Company") entered into a Securities Purchase Agreement (the "Purchase Agreement") with two healthcare-focused investors, pursuant to which the Company agreed to issue in a private placement (the "Offering"), an aggregate of (i) 404,728 shares of the Company’s common stock, $0.001 par value (the "Common Stock"), and (ii) 404,728 shares of Series E Mirroring Preferred Stock

View on SEC.gov

Browse all governance changes →

ORAGENICS INC filing history →

Source: SEC EDGAR

accession 0001493152-23-026968

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.